TipRanks
Advertisement
Advertisement

SE:BINV Stock Latest News

BioInvent Balances Widening Losses With Strong Immuno-Oncology Milestones
Company AnnouncementsBioInvent Balances Widening Losses With Strong Immuno-Oncology Milestones
1M ago
BOVNF Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
BOVNF Upcoming Earnings Report: What to Expect?
1M ago
BioInvent Publishes Key Preclinical Data on TNFR2 Antibodies BI-1808 and BI-1910
PremiumCompany Announcements
BioInvent Publishes Key Preclinical Data on TNFR2 Antibodies BI-1808 and BI-1910
2M ago
BioInvent Wins FDA Fast Track for BI-1808 in High-Need Ovarian Cancer
PremiumCompany Announcements
BioInvent Wins FDA Fast Track for BI-1808 in High-Need Ovarian Cancer
2M ago
BioInvent Data Show FcγR-Targeting Antibodies Boost Checkpoint Therapy and Tackle Resistance
PremiumCompany Announcements
BioInvent Data Show FcγR-Targeting Antibodies Boost Checkpoint Therapy and Tackle Resistance
2M ago
BioInvent’s BI-1808 Shows Promise in Tough Ovarian Cancer Setting
PremiumCompany AnnouncementsBioInvent’s BI-1808 Shows Promise in Tough Ovarian Cancer Setting
3M ago
BioInvent’s BI‑1808 Shows Strong Responses and Immune Activation in Advanced CTCL
Premium
Company Announcements
BioInvent’s BI‑1808 Shows Strong Responses and Immune Activation in Advanced CTCL
4M ago
BioInvent’s BI-1206 Triplet Delivers Strong Efficacy and Safety in Refractory NHL
Premium
Company Announcements
BioInvent’s BI-1206 Triplet Delivers Strong Efficacy and Safety in Refractory NHL
4M ago
BioInvent to Showcase New BI-1206 and BI-1808 Hematology Data at Stockholm KOL Event
PremiumCompany Announcements
BioInvent to Showcase New BI-1206 and BI-1808 Hematology Data at Stockholm KOL Event
4M ago
BioInvent’s BI-1808 Plus Keytruda Shows Strong Ovarian Cancer Signal in Phase 2a
PremiumCompany Announcements
BioInvent’s BI-1808 Plus Keytruda Shows Strong Ovarian Cancer Signal in Phase 2a
5M ago
BioInvent Showcases Promising Ovarian Cancer Antibody BI-1808 in Virtual KOL Event
PremiumCompany Announcements
BioInvent Showcases Promising Ovarian Cancer Antibody BI-1808 in Virtual KOL Event
5M ago
BioInvent to Showcase Promising BI-1206 Triplet Data in Relapsed NHL at EHA 2026
PremiumCompany Announcements
BioInvent to Showcase Promising BI-1206 Triplet Data in Relapsed NHL at EHA 2026
5M ago
BioInvent’s BI-1808 Delivers Promising CTCL Responses in Phase 2a Trial
PremiumCompany AnnouncementsBioInvent’s BI-1808 Delivers Promising CTCL Responses in Phase 2a Trial
5M ago
BioInvent AGM Backs New Incentive Plan, Share Issue Mandate and Board Changes
Premium
Company Announcements
BioInvent AGM Backs New Incentive Plan, Share Issue Mandate and Board Changes
5M ago
BioInvent Ramps Up Oncology Profile With Dual KOL Events Around ASCO and EHA
Premium
Company Announcements
BioInvent Ramps Up Oncology Profile With Dual KOL Events Around ASCO and EHA
5M ago
BioInvent Narrows Focus on Immuno-Oncology as Q1 Loss Widens and Key Trials Advance
PremiumCompany Announcements
BioInvent Narrows Focus on Immuno-Oncology as Q1 Loss Widens and Key Trials Advance
5M ago
BioInvent to showcase promising BI-1808 and KEYTRUDA combo data in recurrent ovarian cancer at ASCO 2026
PremiumCompany Announcements
BioInvent to showcase promising BI-1808 and KEYTRUDA combo data in recurrent ovarian cancer at ASCO 2026
6M ago
BioInvent Narrows Pipeline and Advances Lead Cancer Antibodies in Strategically Focused 2025
PremiumCompany Announcements
BioInvent Narrows Pipeline and Advances Lead Cancer Antibodies in Strategically Focused 2025
6M ago
BioInvent Secures €1 Million Milestone as Endometriosis Antibody Enters Phase 3
PremiumCompany Announcements
BioInvent Secures €1 Million Milestone as Endometriosis Antibody Enters Phase 3
7M ago
BioInvent Calls 2026 AGM, Sets Governance and Voting Framework
PremiumCompany AnnouncementsBioInvent Calls 2026 AGM, Sets Governance and Voting Framework
7M ago
BioInvent Earnings Call: Strong Data, Tight Runway
Premium
Company Announcements
BioInvent Earnings Call: Strong Data, Tight Runway
7M ago
BioInvent doubles down on lead cancer antibodies as 2026 data catalysts loom
Premium
Company Announcements
BioInvent doubles down on lead cancer antibodies as 2026 data catalysts loom
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >